Adjuvant hormone therapy and overall survival among low-grade and apparent early-stage endometrial stromal sarcoma patients
Use of adjuvant hormone therapy for stage I LG-ESS has increased over time though is not associated with OS in this cohort of patients. Additional evaluation is needed to understand the impact of adjuvant hormone therapy on recurrence rates, progression rates, and quality of life to fully understand its value.
Authors
- Morgan Brown (ORCID: https://orcid.org/0000-0002-8927-5830)
- Ashley Sinclair Felix (ORCID: https://orcid.org/0000-0001-8347-9018)
- Kristin Bixel (ORCID: https://orcid.org/0000-0003-2414-3375)
- Caitlin E. Meade (ORCID: https://orcid.org/0009-0005-6417-1399)
Institutions
- The Ohio State University (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3802/jgo.2025.36.e50
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00